Abbott Laboratories $ABT Shares Bought by Abacus Wealth Partners LLC

Abacus Wealth Partners LLC grew its stake in shares of Abbott Laboratories (NYSE:ABT) by 222.5% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 17,769 shares of the healthcare product maker’s stock after acquiring an additional 12,260 shares during the period. Abacus Wealth Partners LLC’s holdings in Abbott Laboratories were worth $2,226,000 at the end of the most recent quarter.

Other hedge funds also recently added to or reduced their stakes in the company. Nia Impact Advisors LLC lifted its position in Abbott Laboratories by 2.2% during the 2nd quarter. Nia Impact Advisors LLC now owns 3,706 shares of the healthcare product maker’s stock worth $504,000 after acquiring an additional 79 shares in the last quarter. American National Bank of Texas lifted its position in Abbott Laboratories by 2.4% during the 4th quarter. American National Bank of Texas now owns 3,408 shares of the healthcare product maker’s stock worth $427,000 after acquiring an additional 79 shares in the last quarter. Connable Office Inc. lifted its position in Abbott Laboratories by 0.5% during the 3rd quarter. Connable Office Inc. now owns 15,042 shares of the healthcare product maker’s stock worth $2,015,000 after acquiring an additional 81 shares in the last quarter. Park Place Capital Corp lifted its position in Abbott Laboratories by 11.0% during the 4th quarter. Park Place Capital Corp now owns 815 shares of the healthcare product maker’s stock worth $102,000 after acquiring an additional 81 shares in the last quarter. Finally, Lantern Wealth Advisors LLC raised its position in shares of Abbott Laboratories by 1.7% in the 3rd quarter. Lantern Wealth Advisors LLC now owns 5,028 shares of the healthcare product maker’s stock valued at $674,000 after purchasing an additional 84 shares in the last quarter. 75.18% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of research firms have recently weighed in on ABT. TD Cowen decreased their price target on shares of Abbott Laboratories from $137.00 to $115.00 and set a “buy” rating for the company in a research report on Friday, April 17th. Sanford C. Bernstein cut their price target on shares of Abbott Laboratories from $125.00 to $110.00 and set an “outperform” rating on the stock in a report on Friday, April 17th. Wells Fargo & Company cut their price target on shares of Abbott Laboratories from $122.00 to $109.00 and set an “overweight” rating on the stock in a report on Friday, April 17th. Bank of America cut their price target on shares of Abbott Laboratories from $150.00 to $120.00 and set a “buy” rating on the stock in a report on Friday, April 17th. Finally, Daiwa Securities Group cut shares of Abbott Laboratories from an “outperform” rating to a “neutral” rating and set a $92.00 price target on the stock. in a report on Wednesday, April 22nd. Two analysts have rated the stock with a Strong Buy rating, nineteen have issued a Buy rating and five have issued a Hold rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $119.43.

Abbott Laboratories Stock Performance

ABT stock opened at $84.49 on Friday. The company has a current ratio of 1.39, a quick ratio of 1.01 and a debt-to-equity ratio of 0.56. The firm has a market cap of $147.16 billion, a P/E ratio of 23.67, a P/E/G ratio of 1.41 and a beta of 0.65. Abbott Laboratories has a 12-month low of $81.97 and a 12-month high of $139.06. The stock’s 50 day simple moving average is $99.02 and its 200 day simple moving average is $113.35.

Abbott Laboratories (NYSE:ABT) last posted its quarterly earnings results on Thursday, April 16th. The healthcare product maker reported $1.15 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.14 by $0.01. The business had revenue of $11.16 billion for the quarter, compared to analyst estimates of $10.99 billion. Abbott Laboratories had a return on equity of 17.62% and a net margin of 13.90%.The business’s revenue was up 7.8% compared to the same quarter last year. During the same period in the prior year, the company posted $1.09 EPS. Abbott Laboratories has set its FY 2026 guidance at 5.380-5.580 EPS and its Q2 2026 guidance at 1.250-1.310 EPS. As a group, equities research analysts predict that Abbott Laboratories will post 5.48 EPS for the current year.

Abbott Laboratories Announces Dividend

The company also recently declared a quarterly dividend, which was paid on Friday, May 15th. Investors of record on Wednesday, April 15th were given a dividend of $0.63 per share. This represents a $2.52 annualized dividend and a dividend yield of 3.0%. The ex-dividend date of this dividend was Wednesday, April 15th. Abbott Laboratories’s dividend payout ratio is currently 70.59%.

Insider Buying and Selling at Abbott Laboratories

In related news, EVP Daniel Gesua Sive Salvadori sold 885 shares of the company’s stock in a transaction on Monday, March 2nd. The stock was sold at an average price of $115.58, for a total transaction of $102,288.30. Following the completion of the transaction, the executive vice president directly owned 146,377 shares in the company, valued at $16,918,253.66. This represents a 0.60% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CFO Philip P. Boudreau acquired 2,200 shares of the stock in a transaction that occurred on Thursday, April 23rd. The shares were bought at an average price of $91.50 per share, with a total value of $201,300.00. Following the completion of the purchase, the chief financial officer owned 2,200 shares in the company, valued at $201,300. The trade was a ∞ increase in their ownership of the stock. The SEC filing for this purchase provides additional information. In the last 90 days, insiders sold 3,055 shares of company stock worth $353,097. 0.46% of the stock is owned by insiders.

Abbott Laboratories Profile

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.